Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


February 24th, 2023

Opthea - Full Recruitment to Trigger Results Countdown

Opthea (OPT: $0.85) is currently conducting two Phase III studies with its ophthalmic drug candidate, OPT-302, for the treatment of wet AMD. Those trials are seeking to recruit just under 2,000 people. With completion of recruitment approaching, that major milestone will trigger a countdown to the pending results a little over 12 months later, which should see considerable interest build in the stock.

February 24th, 2023

Neuren Pharmaceuticals - FDA Decision on Trofinetide Approaching

Arguably the most significant event for the Australian biotech sector is approaching with a decision expected from the FDA on the approval of trofinetide, developed by Neuren Pharmaceuticals (NEU: $7.16), on 12 March.

February 24th, 2023

EBR Systems - Pivotal Results Due Q2

EBR Systems (EBR: $0.60) is a relatively new biotech on the ASX, having listed in November 2021 at $1.08 per share, raising $110 million. It is developing the world's first and only wireless electronic heart pacing system for the left ventricular, called WiSE. It is being trialled with commercially available right ventricle pacers (both with leads and wireless) to offer a novel cardiac resynchronisation therapy (CRT).

February 24th, 2023

Cogstate Acquisition Discussions Halted

Cogstate (CGS: $1.18) came close to being acquired in the recent weeks with discussions with an interested group beginning in December and negotiations ending last week.

February 24th, 2023

Anteris Technologies Raises $35 Million

Aortic heart valve company Anteris Technologies (AVR: $21.71) has completed a $35 million capital raise, conducted at $24 per share. Investors also received a free two-year option to buy an additional share at $29.

February 3rd, 2023

Aroa Biosurgery on Track with Sales and Move to Profitability

Aroa Biosurgery (ARX: $1.15) delivered another consistent quarter of growth. Net cash receipts were up 88% over the PCP to NZ$17 million for the quarter, and up 83% over the PCP for the last nine months to NZ$42 million.



February 3rd, 2023

Bio-Gene Strikes Significant Deal with STK Bio-Ag Technologies

Insecticide development company Bio-Gene Technology (BGT: $0.096) has signed a development and product access deal with Israeli group STK Bio-Ag Technologies.

December 23rd, 2022

Top 6 Stock Picks for 2023

Going into to 2023, Pharmaxis will have two Phase II study results to report. One is with PXS-6302 in the treatment of scars, and the second is with PXS-5505 for the treatment of myelofibrosis.

December 23rd, 2022

2023 Top Six Pick - Aroa Biosurgery: A Defensive Growth Stock for Investors

Wound healing products company Aroa Biosurgery (ARX: $1.10) is proving to be a very predictable performer, meeting or exceeding its sales forecasts.

For the first half of its 2023 financial year (ending 30 September) the company achieved a 44% growth in sales to NZ$29 million. The company is forecasting to be EBITDA neutral by the end of March next year.